Health Canada advises Allergan of its intent to suspend its licences… — public safety notice 59319
Government of Canada recall portal · Canada · 2019-04-04
As described by Government of Canada recall portal: Health Canada advises Allergan of its intent to suspend its licences for Biocell breast implants as a precautionary measure
🏛Compiled from an official source — the facts on this page are reproduced from the issuing authority’s own published notice, which is linked on this page. No AI-generated text appears on this page. How we use AI →
Reported risk: On April 17, Health Canada received a response from Allergan. Departmental experts are currently reviewing this information. Canadians and healthcare professionals will be informed of any further decisions related to the licensing of Biocell breast implants once this review is complete. Original Information Update – April 4, 2019 This follows the completion of Health Canada's scientific assessment of macro-textured implants, as part of its larger ongoing safety review of breast implants and BIA-ALCL, which was launched in November 2018. Health Canada initiated the review because of an increase in Canadian and international cases of BIA-ALCL. As of today, Health Canada has been notified of 28 confirmed Canadian cases of BIA-ALCL, of which 24 (86%) involve Allergan's Biocell breast implant.
Verify each fact at the issuing agency before acting. Recall scope, affected lots, and remediation instructions may be updated by the agency after our last sync.
ProductGuru indexes recall and safety-alert records from ~30 public agency registries. We are not lawyers, regulators or product-safety consultants. This page restates what the named agency published; consult the primary source above (or qualified counsel in your jurisdiction) before any commercial, medical or safety decision.